<DOC>
	<DOCNO>NCT01571726</DOCNO>
	<brief_summary>Background : - Multiple myeloma ( MM ) type malignant blood cancer . It affect plasma cell , help produce antibody fight infection . MM nearly always precede pre-malignant state , monoclonal gammopathy undetermined significance ( MGUS ) smolder multiple myeloma ( SMM ) . Currently , possible predict someone MGUS SMM develop MM . Also , disease change early state well understood . Researchers want look image study people MGUS , SMM , MM . They study whether growth blood vessel use predict disease progression . Objectives : - To use imaging study evaluate disease progression multiple myeloma . Eligibility : - Individuals least 18 year age MGUS , SMM , newly diagnose MM . Design : - Participants screen physical exam medical history . They also blood urine test , provide bone marrow sample . - Participants positron emission tomography ( PET ) scan new contrast agent [ 18 ] F-Fluciclatide . The contrast agent intend show pattern increase vessel growth bone marrow . - Participants also magnetic resonance imaging ( MRI ) scan . This scan do accord standard procedure . - Researchers compare scan blood test clinical information study disease progression MGUS , SMM , MM ... .</brief_summary>
	<brief_title>Imaging Studies Development Multiple Myeloma</brief_title>
	<detailed_description>Background : - Multiple myeloma ( MM ) plasma cell neoplasm median survival 3-4 year . - Monoclonal gammopathy undetermined significance ( MGUS ) smolder myeloma ( SMM ) premalignant plasma cell proliferative disorder characterize elevated monoclonal protein bone marrow plasma cell . MGUS affect 3.2 % Caucasians age 50 1 % annual risk progression MM . Approximately 3,000 case SMM diagnose annually 10 % annual risk progression MM . - Currently , possible predict patient progress MM , biological change occur precursor state remain poorly understood . - Angiogenesis hallmark multiple myeloma precursor disease . Angiogenesis measure use microvessel density . In prior study , demonstrate increased microvessel density use CD34 immunohistochemistry patient multiple myeloma , compare SMM MGUS , suggest increase vascular density disease progress . A correlation MM disease stage prognosis report several serum angiogenic factor myeloma cell bone marrow endothelial cell show secrete respond angiogenic modulators . - Dynamic contrast-enhanced ( DCE ) -MRI noninvasive way evaluate angiogenesis . In prior NIH study , demonstrate kep ( measure contrast influx vessel bone marrow microenvironment ) gradually high MM &gt; SMM &gt; MGUS , however limited image single field view ( i.e . lumbar spine ) . This also highly correlated microvessel density . - Fluciclatide small cyclic peptide contain RGD tri-peptide , preferentially bind high affinity Alpha ( v ) Beta ( 3 ) integrins , up-regulated angiogenesis . - Alpha ( v ) Beta ( 3 ) integrins also express certain type tumor cell activiated osteoclast . - ( 18 ) Fluciclatide ( previously know ( 18 ) F-AH111585 ) new radiopharmaceutical develop PET image , target Alpha ( v ) Beta ( 3 ) receptor . - Novel image modality use tracer specific angiogenesis , use ( 18 ) F-Fluciclatide whole-body PET/CT imaging may improve ability predict patient high risk progression . Objectives : - The primary objective study explore distribution ( 18 ) F-Fluciclatide PET/CT bone marrow microenvironment patient multiple myeloma precursor disease . - The secondary objective preliminarily evaluate distribution ( 18 ) Fluciclatide PET/CT respect DCE-MRI bone marrow vascularity determine immunohistochemistry ( CD34 ) bone marrow biopsy specimen . - To preliminarily evaluate distribution ( 18 ) F-Fluciclatide PET/CT respect establish clinical marker progression MGUS/SMM MM , include serum M-protein , percentage plasma cell bone marrow , serum free light-chain abnormality immunoparesis , ratio normal/abnormal plasma cell bone marrow flow cytometry . Eligibility : - A confirmed diagnosis MGUS , SMM MM ( base IMWG diagnostic criterion ) - Age great equal 18 year - ECOG performance status range 0-2 Design : - This cross-sectional pilot study patient MGUS , SMM MM . - Subjects frank multiple myeloma enrol first . If ( 18 ) F-Fluciclatide PET/CT negative first 5 subject , study abort proceed MGUS SMM patient . However 18F-Fluciclatide PET/CT positive MM patient , proceed MGUS SMM patient . - Subsequently ( 18 ) F-Fluciclatide PET/CT DCE-MRI image do patient . When feasible , optional non-contrast wholebody MR may also perform . - 10 MM , 10 SMM 10 MGUS patient enrol protocol . - Patients may donate cellular product tissue appropriate research purpose .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Paraproteinemias</mesh_term>
	<mesh_term>Monoclonal Gammopathy Undetermined Significance</mesh_term>
	<criteria>INCLUSION CRITERIA : Diagnosis MGUS , SMM MM make accordance clinical diagnostic criterion set forth International Myeloma Working Group . The diagnosis confirm following diagnostic test : serum/urine protein electrophoresis serum/urine immunofixation , lightchain assay , skeletal survey , immunohistochemistry analysis bone marrow biopsy , combination NIH Note : Written result institution outside NIH test accept available . Age great equal 18 year . ECOG performance status 02 . The patient must competent sign inform consent form . Platelet count = &gt; 100,000 . Subjects must weight &lt; 320lbs Creatinine &lt; 2.5 time ULN eGFR &gt; 30 ml/min/1.73m ( 2 ) EXCLUSION CRITERIA : A medical history malignancy ( apart basal cell carcinoma skin situ cervical carcinoma ; also , MM patient include MM ) except patient free symptom without active therapy least previous 3 year . Patients document metastatic lesion another type malignancy exclude . Female subject pregnant breastfeeding . The subject know allergy gadolinium The subject contraindication MRI Subjects must weigh &lt; 136 kg ( weight limit scanner table ) . Subjects pacemaker , cerebral aneurysm clip , shrapnel injury , implant electronic device metal compatible MRI .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 16, 2014</verification_date>
	<keyword>( 18 ) -Fluciclatide PET/CT</keyword>
	<keyword>Serum M-Protein</keyword>
	<keyword>Percentage Plasma Cells Bone Marrow</keyword>
	<keyword>Ratio Normal/Abnormal Percentage Plasma Cells Bone Marrow</keyword>
	<keyword>Multiple Myeloma</keyword>
</DOC>